.png)
- Ha Protik
- Sep 6, 2024
- 4 min read
Abbott
Consumer Biowearables Market:
Abbott has entered the U.S. consumer wearables market with two new over-the-counter continuous glucose monitoring systems: Lingo and Libre Rio. These systems received FDA clearance, further solidifying Abbott’s leading position in biowearables.
Diagnostics Sales Growth:
In the fourth quarter of 2021, Abbott’s worldwide diagnostics sales increased by 2.9% on a reported basis and 3.3% organically. Global COVID-19 testing-related sales contributed significantly, including sales from Abbott’s BinaxNOW®, Panbio®, and ID NOW® rapid testing platforms.
Laboratory Automation System Approval:
BD
BD and Quest Diagnostics have joined forces in a global collaboration agreement to develop, manufacture, and commercialize flow cytometry-based companion diagnostics (CDx). These CDx are intended to help select the best treatment for patients with cancer and other diseases. The collaboration aims to provide an end-to-end solution for CDx development, ranging from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits1.
Flow cytometry, an established laboratory technology, is now being applied in the development of companion diagnostics. It can rapidly analyze and sort individual cells, enabling healthcare providers to understand an individual’s immune response and potentially improve clinical outcomes. Through this collaboration, BD and Quest Diagnostics aim to bring novel companion diagnostics to market, enhancing precision healthcare and reducing costs1.
Fresenius Kabi
summary of recent news related to Fresenius Kabi:
Trailblazer Award:
Fresenius Kabi received the 2024 Trailblazer Award from Premier Inc. for Supply Chain Innovation. This award recognizes their innovative and scalable methods and technology that accelerate clinical evidence into real-world practice1.
Q2 Performance:
In Q2, Fresenius Kabi demonstrated excellent performance, citing strong results from its Kabi and Helios units. The company made significant progress in deleveraging and remains optimistic about the second half of the year2.
Biosimilar Candidates:
Fresenius Kabi and Formycon received a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) for their biosimilar candidate, FYB202 (Ustekinumab). It is intended for the treatment of severe inflammatory diseases in fields such as gastroenterology, dermatology, and rheumatology3.
Additionally, the European Medicines Agency accepted the Marketing Authorization Applications for biosimilar candidates of Prolia® (denosumab) and Xgeva® (denosumab)4.
Diagnostic Agents:
Fresenius Kabi expanded its radiology portfolio with Sincalide for Injection, an authorized generic for Kinevac®. This diagnostic pharmaceutical agent aids in diagnosing gallbladder, intestinal, and pancreatic issues5.
They also launched Gadobutrol Injection, a generic substitute for the contrast agent Gadavist®, used in magnetic resonance imaging (MRI) procedures6.
Polymed
Some recent updates related to Poly Medicure Limited (Polymed) and their diagnostics division:
Revenue Growth and Guidance:
Polymed has posted a strong set of Q2 numbers, leading them to increase their revenue guidance for FY24. They now target revenue growth of 22-24%.
The company’s focus areas include blood collection tubes, needles, and lab disposables1.
Awards and Recognition:
Investment in Innovation:
Himanshu Baid, MD of Polymed, emphasized their commitment to investing in new technologies and innovations for better patient care.
The company plans to invest Rs 50 crore in capacity expansion over the next two years1.
Forward-Looking Policy:
Polymed welcomes India’s forward-looking policy for medical devices, which aims to foster innovation and improve healthcare accessibility.
Siemens
Siemens Healthineers has been at the forefront of diagnostic innovations. Here are some recent advancements:
Atellica Solution: This is a high-throughput immunoassay and clinical chemistry system that streamlines workflow, reduces sample volume, and enhances efficiency in laboratories.
CLINITEST Rapid COVID-19 Antigen Test: A point-of-care test for detecting SARS-CoV-2 antigens, providing results in just 15 minutes.
ADVIA Centaur XPT Immunoassay System: An advanced platform for infectious disease testing, cardiac markers, and other critical assays.
MAGNETOM Free.Max MRI Scanner: Siemens Healthineers’ latest MRI system with a large 80 cm bore, enabling better patient comfort and faster imaging.
syngo Virtual Cockpit: A remote assistance platform that allows experts to guide less experienced technologists during complex procedures.
Immucor
Immucor, a global leader in transfusion and transplantation diagnostics, has made significant advancements in their field. Here are the recent innovations:
MIA FORA® NGS EXPRESS HLA Typing Software: Immucor launched this software globally. It provides a faster and easier next-generation sequencing (NGS) analysis experience for users of MIA FORA NGS MFlex HLA Typing assays. EXPRESS allows analysis on both standard Windows desktop systems and Linux servers. It’s a precise solution for genotyping calls and alignment1.
LIFECODES® LSA Class I and Class II Assays: These enhanced performance Luminex® single antigen products received FDA clearance in the United States. They demonstrate a lower false positive rate, improving the ability to find acceptable donors for transplant patients1.
MATCH IT!® Antibody Software: This software, also FDA-cleared, complements the LIFECODES LSA Assays. It’s a key component in Immucor’s transplant antibody portfolio, benefiting laboratories, transplant teams, and patients1.
These innovations reflect Immucor’s commitment to advancing histocompatibility testing and improving patient outcomes.